Bellerophon Therapeutics, Inc. 4
4 · Bellerophon Therapeutics, Inc. · Filed Dec 9, 2016
Insider Transaction Report
Form 4
Tenenbaum Fabian
Chief Executive Officer
Transactions
- Award
Stock Option (right to buy)
2016-12-07+1,042,556→ 1,042,556 totalExercise: $0.49Exp: 2026-12-06→ Common Stock (1,042,556 underlying)
Footnotes (1)
- [F1]The option grant was approved by Bellerophon Therapeutics, Inc.'s board of directors on December 7, 2016, subject to stockholder approval of an amendment to the stock option plan under which the option was granted.